COPAXONE® FAQs
Below you’ll find some of the most frequently asked questions—and a few that are not so common—concerning COPAXONE®. For the answers, click on a question or select the Show All button to see all the answers.
References:
1. Ford C, Goodman AD, Johnson K, et al. Mult Scler. 2010;16(3):342-350. 2. Data on file. Teva Neuroscience, Inc. 3. Miller A, Shapiro S, Gershtein R, et al. J Neuroimmunol. 1998;92(1-2):113-121. 4. Ziemssen T, Kümpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Brain. 2002;125(Pt11):2381-2391. 5. Chen M, Valenzuela RM, Dhib-Jalbut S. J Neurol Sci. 2003;215(1-2):37-44. 6. Johnson KP, Brooks BR, Cohen JA, et al. Neurology. 1995;45(7):1268-1276. 7. Bornstein MB, Miller A, Slagle S, et al. N Engl J Med. 1987;317(7):408-414. 8. Comi G, Filippi M, Wolinsky JS. Ann Neurol. 2001;49(3):290-297. 9. Goodin DS, Frohman EM, Garmany GP, et al. Neurology. 2002;58(2):169-178. 10. COPAXONE® prescribing information. Teva Pharmaceutical Industries Ltd. 11. Vaccinations. National Multiple Sclerosis Society Web site. http://www.nationalmssociety.org/living-with-multiple-sclerosis/healthy-living/vaccinations/index.aspx. Accessed September 15, 2010. 12. 2009 H1N1 Flu and You. CDC Web site. http://www.cdc.gov/h1n1flu/qa.htm. Last updated August 11, 2010. Accessed September 23, 2010.